在胃肠道癌症患者服用阿纳莫雷林后的内分泌学变化
Sakiko Kuraoka1, Masaya Iwamuro1, Takuya Satomi1
1Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Acta medica Okayama
|June 26, 2023
概括
在癌症缓冲症患者的阿纳莫雷林治疗3周内增加了体重和生长激素水平. 长期使用 (≥12周) 显示了持续的合成代谢效应,这表明对管理与癌症相关的衰竭有潜在的益处.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 代谢过程中的代谢.
背景情况:
- 癌症缓解症显著影响患者的健康和生活质量.
- 与癌症缓解症相关的荷尔蒙变化需要进一步调查.
- 亚纳莫雷林是一种潜在的治疗癌症缓解症的治疗剂.
研究的目的:
- 为了研究阿纳莫雷林对肠内分泌系统参数的影响,在患有胃肠道癌症和缓解症的患者中.
- 为了评估体重,白蛋白,HbA1c和激素水平在阿纳莫雷林后的变化.
主要方法:
- 一项前性研究,招募了13名患有胃肠道癌症和缓冲症的患者.
- 在基线,3周和12周评估体重,血清白蛋白,HbA1c和激素水平.
- 分析激素变化和体重变化之间的相关性.
主要成果:
- 阿纳莫雷林的使用导致3周后体重增加.
- 3周后观察到生长激素,HbA1c和IGF-1 SD得分的显著增加.
- 3周IGF-1 SD得分与TSH/自由之间的负相关性; 12周IGF-1 SD得分与体重之间的正相关性.
结论:
- 在3周内,阿纳莫雷林会影响诸如TSH和自由这样的内分泌参数.
- 荷尔蒙水平在初始变化后倾向于平衡.
- 长期使用 (≥12周) 时,阿纳莫雷林的合成效应明显.
相关概念视频
Glucagon-like Receptor Agonists
366
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366
Regulation of Food Intake
289
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
289
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
412
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
412
Gastric Emptying
969
Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
969
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
316
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
316


